thanks for sharing, Sandy. imo - vaccines logistics for DKSH will be a bonus if they gets it given their proven and accredited technologically advanced cold chain facilities specifically for healthcare; leveraging its existing healthcare distribution center at Shah Alam and Kota Kinabalu. Both centers complied with regulatory and industry standards for pharma/medical device - GDP, GDPMD and ISO 9001/13485 certified. What attracted me is not vaccines prospect but rather the resilience and strength within the company's culture. One example is the $480M acquisition of Auric Pacific that was completed and consolidated in Apr 2019. This acquisition is a huge success by bringing in Buttercup and SCS butter products into its FMCG line ups and return of investment is expected to be realized by end of 2020. ROI within 2 years is amazing. Within the corporate itself, there were a few more acquisitions which are impressive namely Axieo and Crossmark in 2020. With the damage caused by Covid, the corporate headquarters strategies will be focusing on its bottom line with asset light and cash flow strategy moving forward. Benefits of Auric Pacific will be realized starting 2020 through 2021. Some of the results can be seen from the recent QR. Just my opinions, could be wrong. Hope it helps.

Hi Maggie, only IBs can provide price recommendations. For retail investors, we can just analyse as much information that is available and make necessary decision. As for DKSH, top 30 shareholders are holding close to 90% of the total outstanding shares based on 2019 annual report. A big spread between bid and asks is expected. The next QR which is Q4’20 will probably provides more clarity on its focus towards manoeuvring through CMCO. There is no rush and you should at least go through it’s reports first before making decision. Just my opinions, could be wrong. Hope it helps.

DKSH is involved in healthcare, consumer products, and tech. With the weighted average PE ratio of each of those sectors in Bursa Malaysia of 32.5 and DKSH's EPS of 0.31 (TTM), the target price for DKSH should be RM 10.08. Even if you use DKSH's EPS in 2020 (3 quarters only) of 0.22, the target price should be RM 7.15, i.e. double the current pricing. This is all without any vaccine related news. With recent Pfizer vaccine announcements and with DKSH's cold storage logistics + being Pfizer's par

Hi, cheng. I'm not sure if you still have D&O, but if you're keeping, you really hit the jackpot! Looks like your new stock is DKSH, an established distribution company. What was it about DKSH that attracted you? Was it the vaccine distribution prospects or the improving profitability?

Hi Benjamin, not anymore :) D&O has been a good ride and I am keeping it in the watchlist for now until the price is attractive again. As for DKSH, it is the tangible results of improving profitability coming from Auric Pacific acquisition at the back of economic destruction from the pandemic; comparing qoq and yoy (cumulative) if you will. In terms of prospects, there are two areas of opportunity for DKSH (1) global demand for refrigerated shipped goods is on the rise and will continue to expand - foods, beverages and pharmaceuticals. Refrigerated shipping containers demand is expected to grow at 10.2% CAGR through 2025. As such, demand for refrigerated trucks and climate controlled warehouse will rise too. DKSH has a 510k sqft distribution center at Klang; ambient and temperature controlled for Consumer Goods. Healthcare distribution centers at Shah Alam and Kota Kinabalu. (2) RCEP - touted to be the world's largest trading bloc that promises to speed up its member's post pandemic growth. Its about trade of goods, investments, telecommunications, financial services, ecommerce, IPs and etc. I think this is also a huge prospects for DKSH if they can tap into it.